Navigation Links
Robotic Surgery Expert Dr. David Samadi, MD Discusses FDA Warnings on the Effect of GnRH Agonists
Date:10/27/2010

NEW YORK, Oct. 27 /PRNewswire/ -- Drugs, known as gonadotropin-releasing hormone (GnRH) agonists, may raise diabetes and heart risk and, as a result, now need new warnings. U.S. health officials said the drug used to stem the production of testosterone, the hormone that contributes to prostate cancer growth, could also lead to sudden death. "The risk of diabetes, heart disease and sudden death in men undergoing prostate cancer treatment with these drugs does not appear to be elevated, however patients should be regularly monitored by their doctors for signs of blood sugar increase or heart damage," said Dr. David Samadi, a robotic prostatectomy expert as well as the new Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

(Logo: http://photos.prnewswire.com/prnh/20100921/NY69144LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100921/NY69144LOGO)

"Doctors need to monitor a prostate cancer patient's risk for diabetes and heart disease before starting any treatment and compare the side effects versus benefits," said Dr. Samadi, a urologic oncologist skilled in robotic prostate surgery. GnRH agonists are approved by the Food and Drug Administration to alleviate symptoms of advanced prostate cancer with androgen deprivation therapy treatment. These include Abbott's Lupron, AstraZeneca's Zoladex, Sanofi's Eligard, Watson Pharmaceuticals' Trelstar, Endo Pharmaceuticals' Vantas, Alza's Viadur, Pfizer's Synarel and several generic versions.

The medical journal Circulation reported in February that various doctors' groups felt androgen deprivation hormone treatment for prostate cancer was believed to increase the risk of heart attack in patients with a prostate cancer diagnosis. Subsequent studies reported by the FDA determined a small increased risk of diabetes or heart disease in patients treated with these drugs. "Prostate cancer patients do not have to stop taking the drugs, but they go to their doctors with any concerns," said Dr. Samadi, "Patients should tell their doctors if they have ever had diabetes, heart disease, heart attack, stroke, history of high blood pressure, high cholesterol or if they are smokers."

All of these medicines for prostate cancer are allowed to remain on the market but must carry new label warnings. The drug manufacturers are currently reviewing the FDA request. "What's important to note is that hormone treatment for prostate cancer is not a fail-safe cure, because even though the therapy can extend survival, the prostate cancer tumors can eventually become immune to therapy," explained Dr. Samadi. Evidence has shown that lowering testosterone is an effective prostate cancer treatment, however lower testosterone levels can induce metabolic syndrome, which contributes to the development of heart disease. Men diagnosed with advanced prostate cancer who are on hormone therapy are at a twofold risk of developing metabolic syndrome.

"I routinely counsel my prostate cancer patients on the risks of weight gain and increased carbohydrate intake and advise them to eat sensibly and exercise in order to reduce their risk of developing metabolic syndrome," said Dr. Samadi, "These GnRH agonists might increase heart disease risks because they cause men to pack on extra weight, and, as usual, appropriate lifestyle choices are the best course of action in preventing prostate cancer or other disease."

GnRH agonists are routinely used in conjunction with radiation therapy, which is why Dr. Samadi advocates the use of robotic prostatectomy over radiation. "It's the only treatment that completely removes the cancerous prostate gland without the need for hormones or radiation, and allows me to determine its stage, level and grade accurately," explained Samadi, "What's the point in preventing these patients from dying of prostate cancer if they are just going to die from heart disease? It makes no sense."Contact:  Dr. David B. Samadi  1-888-762-6810http://www.smart-surgery.com
'/>"/>

SOURCE www.Smart-Surgery.com
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardicas Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting
2. Upstate New York Laboratory Robotics Interest Group (LRIG) to Host Free Symposium and Exhibition
3. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
4. Health Robotics Expands Operations Into Bosnia, Croatia, Finland, Macedonia, Montenegro, Serbia, and Slovenia
5. 100,000th Patient Treated With Accurays CyberKnife® Robotic Radiosurgery System
6. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
7. International Robotic Urology Symposium 2011
8. Health Robotics Continues Worldwide Distribution Channel Expansion in Bulgaria, Czech Republic, Romania and Slovakia
9. Robotic Prostatectomy Expert Dr. David Samadi, MD Introduces His SMART Surgery Website for Prostate Cancer Treatment Education
10. Robotic Prostatectomy Expert Dr. David Samadi, MD Talks About Prostate Cancer Treatment News and Developments
11. Robotic Surgery Expert Dr. David B. Samadi, MD Discusses New Evidence That Proves The Low Complication Rates of Robotic Prostatectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 Laboratory glassware ... in laboratories. These may range from microscope slides to ... is made from borosilicate glass because of its low ... the other hand, started gaining popularity over the past ... to replace glass with plastic in several applications due ...
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... 11, 2016  NOIT™ Research LLC, a private, leading-edge ... Change" campaign to assist needy families in obtaining one ... sold between February 10, 2016 and March 31, 2016, ... family. The NOIT is an auditory stimulus that plays ... language skills. Beth Shier , NOIT ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television ... a demanding job, and no time to decompress, Rabinowitz found herself drawn to a ... meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with her ...
(Date:2/12/2016)... ... 12, 2016 , ... Itopia, a leader in cloud services ... Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This ... small and medium business (SMB) clients. , In recent years, BI ...
(Date:2/12/2016)... ... 2016 , ... The Jones Agency, a family owned insurance company with offices ... cooperative charity drive with the Tarrant Area Food Bank in the hopes of alleviating ... in need, the Tarrant County Food Bank offers hope and security to the one ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... NY (PRWEB) , ... February 12, 2016 , ... ... of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer ... Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately ...
Breaking Medicine News(10 mins):